NASDAQ:MREO

Mereo BioPharma Group - MREO Stock Forecast, Price & News

$0.82

-0.01 (-1.25%)

(As of 12/6/2022 09:48 AM ET)

Add

Compare

Today's Range: $0.82
▼
$0.82
50-Day Range: $0.71
▼
$1.01
52-Week Range: $0.30
▼
$1.86

Volume: 82 shs
Average Volume: 449,419 shs
Market Capitalization: $102.74 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.25

Mereo BioPharma Group MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 538.7% Upside
$5.25 Price Target
Short Interest: Healthy
4.08% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.41) to ($0.06) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

737th out of 1,023 stocks

Pharmaceutical Preparations Industry

356th out of 501 stocks

3.5

Analyst's Opinion

Consensus Rating
Mereo BioPharma Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.25, Mereo BioPharma Group has a forecasted upside of 538.7% from its current price of $0.82.
Amount of Analyst Coverage
Mereo BioPharma Group has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.08% of the outstanding shares of Mereo BioPharma Group have been sold short.
Short Interest Ratio / Days to Cover
Mereo BioPharma Group has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
Change versus previous month
Short interest in Mereo BioPharma Group has recently decreased by 10.68%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Mereo BioPharma Group does not currently pay a dividend.
Dividend Growth
Mereo BioPharma Group does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MREO.

0.0

News and Social Media Coverage

Search Interest
Only 2 people have searched for MREO on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Mereo BioPharma Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mereo BioPharma Group insiders have not sold or bought any company stock.
Percentage Held by Institutions
57.55% of the stock of Mereo BioPharma Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Mereo BioPharma Group are expected to grow in the coming year, from ($0.41) to ($0.06) per share.
Price to Book Value per Share Ratio
Mereo BioPharma Group has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Mereo BioPharma Group (NASDAQ:MREO) Stock

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Receive MREO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter.

MREO Stock News Headlines

November 15, 2022 | finance.yahoo.com

MEREO BIOPHARMA (MREO) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

November 8, 2022 | finance.yahoo.com

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

October 25, 2022 | finance.yahoo.com

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

October 21, 2022 | finance.yahoo.com

Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

October 18, 2022 | finance.yahoo.com

Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan

October 18, 2022 | finance.yahoo.com

Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value

October 3, 2022 | finance.yahoo.com

Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders

October 3, 2022 | finance.yahoo.com

Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five

September 14, 2022 | finance.yahoo.com

Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders

September 12, 2022 | finance.yahoo.com

Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors

June 20, 2022 | finance.yahoo.com

Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout

June 2, 2022 | finance.yahoo.com

Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan

May 26, 2022 | finance.yahoo.com

Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting

May 17, 2022 | finance.yahoo.com

Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors

May 9, 2022 | seekingalpha.com

Mereo Biopharma stock rises as alvelestat high dose shows promise in lung disease in phase 2 trial

May 9, 2022 | finance.yahoo.com

Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema

May 6, 2022 | finance.yahoo.com

Mereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat

May 6, 2022 | finance.yahoo.com

Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat

April 22, 2022 | finance.yahoo.com

MEREO BIOPHARMA (MREO) Loses 38.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

April 6, 2022 | finance.yahoo.com

Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference

March 31, 2022 | finance.yahoo.com

Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights

March 3, 2022 | finance.yahoo.com

Mereo BioPharma to Hold Virtual R&D Day on Monday, March 14, 2022

February 10, 2022 | finance.yahoo.com

Mereo BioPharma to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference

January 20, 2022 | nasdaq.com

Mereo BioPharma Group plc American Depositary Shares (MREO)

January 10, 2022 | nasdaq.com

Mereo Biopharma Group Plc - ADR Shares Near 52-Week Low - Market Mover

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MREO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter.

MREO Company Calendar

Today: 12/06/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MREO
CUSIP: N/A
CIK: 1719714
Web: www.mereobiopharma.com
Phone: 44-33-3023-7300
Fax: N/A
Employees: 38
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.25
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +538.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.32
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $50.14 million
Price / Sales: 2.05
Cash Flow: $0.15 per share
Price / Cash Flow: 5.33
Book Value: $1.03 per share
Price / Book: 0.80

Miscellaneous

Outstanding Shares: 124,990,000
Free Float: N/A
Market Cap: $102.74 million
Optionable: Not Optionable
Beta: 0.86

Key Executives

Dr. Denise Scots-Knight Ph.D. (Age 63)
Co-Founder, CEO & Exec. Director
Comp: $833.03k

Mr. Charles Sermon (Age 53)
Co-Founder, Gen. Counsel & Company Sec.

Dr. Alastair MacKinnon M.D. (Age 52)
MBBS, Co-Founder and Chief of Portfolio & Pipeline Strategy

Dr. John P. Richard M.B.A. (Age 65)
MBA, Co-Founder & Chief Bus. Officer

Ms. Christine Fox CPA (Age 41)
Chief Financial Officer

Dr. John A. Lewicki Ph.D. (Age 70)
Chief Scientific Officer

Dr. Jackie Parkin
Therapy Area Head of Respiratory Endocrinology

Ms. Alexandra Hughes-Wilson (Age 51)
Chief of Patient Access & Commercial Planning

Dr. Suba Krishnan
Sr. VP of Clinical Devel.

Dr. Fiona Bor
Head of Intellectual Property

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MREO Stock - Frequently Asked Questions

Should I buy or sell Mereo BioPharma Group stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mereo BioPharma Group in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MREO shares.
View MREO analyst ratings or view top-rated stocks.
What is Mereo BioPharma Group's stock price forecast for 2023?: 4 equities research analysts have issued 12-month price objectives for Mereo BioPharma Group's stock. Their MREO share price forecasts range from $4.00 to $8.00. On average, they expect the company's stock price to reach $5.25 in the next twelve months. This suggests a possible upside of 538.7% from the stock's current price.
View analysts price targets for MREO or view top-rated stocks among Wall Street analysts.
How have MREO shares performed in 2022?: Mereo BioPharma Group's stock was trading at $1.60 at the beginning of the year. Since then, MREO stock has decreased by 48.6% and is now trading at $0.8220.
View the best growth stocks for 2022 here.
What other stocks do shareholders of Mereo BioPharma Group own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Mereo BioPharma Group investors own include VBI Vaccines (VBIV), Pfizer (PFE), Otonomy (OTIC), OpGen (OPGN), OPKO Health (OPK), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Vaxart (VXRT), Aduro Biotech (ADRO) and Affimed (afmd).

When did Mereo BioPharma Group IPO?: (MREO) raised $49 million in an IPO on the week of April 23rd 2018. The company issued 2,800,000 shares at a price of $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers.
What is Mereo BioPharma Group's stock symbol?: Mereo BioPharma Group trades on the NASDAQ under the ticker symbol "MREO."
Who are Mereo BioPharma Group's major shareholders?: Mereo BioPharma Group's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Rubric Capital Management LP (8.29%), Point72 Asset Management L.P. (7.86%), Clearline Capital LP (3.17%), Renaissance Technologies LLC (0.99%), BlackRock Inc. (0.53%) and Monaco Asset Management SAM (0.16%).
How do I buy shares of Mereo BioPharma Group?: Shares of MREO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Mereo BioPharma Group's stock price today?: One share of MREO stock can currently be purchased for approximately $0.82.
How much money does Mereo BioPharma Group make?: Mereo BioPharma Group (NASDAQ:MREO) has a market capitalization of $102.74 million and generates $50.14 million in revenue each year.
How can I contact Mereo BioPharma Group?: Mereo BioPharma Group's mailing address is ONE CAVENDISH PLACE FOURTH FLOOR, LONDON X0, W1G0QF. The official website for the company is www.mereobiopharma.com. The company can be reached via phone at 44-33-3023-7300 or via email at investors@mereobiopharma.com.

This page (NASDAQ:MREO) was last updated on 12/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial